Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia.

Front Immunol · 2025 · PMC12043577 · PMID 40313949

Europe PMC DOI

hedged sentence

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

marginally significantP =0.078so close (0.05 < p ≤ 0.1)

The multivariate analysis identified a significant correlation between the age group of ≥ 40 years and a high ( P =0.018; Figure 2 ), as well as a marginally significant association between the presence of transcription-related gene mutations and an improved ORR ( P =0.078; Figure 2 ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.